Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Recent work by the PolyPeptide Group, a Swiss contract manufacturing organization (CMO), shows that green chemistry is not only feasible, but also is economically sound.
Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
A platform trial is also efficient in that it enables the investigators to share placebo information.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
PRESS RELEASES